Shopping Cart 0
Cart Subtotal
USD 0

Novus Therapeutics Inc (NVUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Novus Therapeutics Inc (Tokai Pharma), formerly Tokai Pharmaceuticals Inc is a pharmaceutical company that develops products for ear, nose and throat. The company's lead products is a nasally-administer, combination drug product and eustachian tube dysfunction, among others. Its galeterone is an oral small molecule drug candidate with treatment of patients with metastatic castration-resistant prostate cancer. Novus Therapeutics offers OP-02 surfactant program and OP-01 foam platform. Its pipeline also includes androgen receptor degradation agent's drug discovery program to identify and develop compounds for androgen receptor degradation activity. The company develops treatments for illnesses and disorders of the ears, nose, and throat. It has collaboration with pharmaceutical companies to enhance its product candidates. Novus Therapeutics is headquartered in Irvine, California, the US.

Novus Therapeutics Inc (NVUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Novus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Novus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Tokai Pharma Raises USD 35.5 Million In Series E Financing 11

Partnerships 13

Tokai Pharma Expands Agreement with Qiagen 13

Tokai Pharma Expands Agreement with Qiagen 14

Licensing Agreements 15

Otic Pharma Enters into Licensing Agreement with Otodyne 15

Tokai Pharma Enters into Licensing Agreement with Johns Hopkins University 16

Tokai Pharma Amends Licensing Agreement with University of Maryland, Baltimore 17

Equity Offering 18

Novus Therapeutics Postpones Public Offering of Shares 18

Novus Therapeutics Plans to Raise up to USD150 Million in Public Offering of Securities 20

Novus Therapeutics Plans to Raise up to USD8.5 Million in Public Offering of Shares 21

Novus Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 22

Tokai Pharma Raises USD0.71 Million in Public Offering of Shares 23

Tokai Pharma Raises USD97.2 Million in IPO 24

Acquisition 26

Tokai Pharma Acquires Otic Pharma 26

Novus Therapeutics Inc-Key Competitors 28

Novus Therapeutics Inc-Key Employees 29

Novus Therapeutics Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 07, 2018: Novus Therapeutics Reports Second Quarter 2018 Financial Results 31

May 11, 2018: Novus Therapeutics Reports First Quarter 2018 Financial Results 32

Apr 02, 2018: Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 33

Nov 08, 2017: Novus Therapeutics Reports Third Quarter 2017 Results 34

Aug 09, 2017: Novus Therapeutics Reports Second Quarter 2017 Results 35

Corporate Communications 36

Nov 06, 2017: Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President 36

Jun 12, 2017: Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Novus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Novus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Novus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Novus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Tokai Pharma Raises USD 35.5 Million In Series E Financing 11

Tokai Pharma Expands Agreement with Qiagen 13

Tokai Pharma Expands Agreement with Qiagen 14

Otic Pharma Enters into Licensing Agreement with Otodyne 15

Tokai Pharma Enters into Licensing Agreement with Johns Hopkins University 16

Tokai Pharma Amends Licensing Agreement with University of Maryland, Baltimore 17

Novus Therapeutics Postpones Public Offering of Shares 18

Novus Therapeutics Plans to Raise up to USD150 Million in Public Offering of Securities 20

Novus Therapeutics Plans to Raise up to USD8.5 Million in Public Offering of Shares 21

Novus Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 22

Tokai Pharma Raises USD0.71 Million in Public Offering of Shares 23

Tokai Pharma Raises USD97.2 Million in IPO 24

Tokai Pharma Acquires Otic Pharma 26

Novus Therapeutics Inc, Key Competitors 28

Novus Therapeutics Inc, Key Employees 29

Novus Therapeutics Inc, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Novus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.